| Literature DB >> 32085755 |
Fatemeh Nazari1,2, Vahid Shaygannejad3,4, Mehrdad Mohammadi Sichani5,6, Marjan Mansourian7, Valiollah Hajhashemi8,9.
Abstract
BACKGROUND: Sexual function is a component of quality of life, and sexual dysfunction entails reduced satisfaction with life and impaired mood and quality of relationships and affects not only the individual's quality of life, but her partner's life as well. Since Sexual Dysfunction (SD) is among the most common complaints of patients with Multiple Sclerosis (MS), this study was conducted to determine the prevalence of SD among women with MS and its effect on quality of life.Entities:
Keywords: Multiple sclerosis; Prevalence; Sexual dysfunction; Women
Mesh:
Year: 2020 PMID: 32085755 PMCID: PMC7035744 DOI: 10.1186/s12894-020-0581-2
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Demographic and clinical variables in the study subjects
| Variable | Mean (±SD) | Minimum | Maximum | |
|---|---|---|---|---|
| Age (years) | 36.35 ± 7.33 | 22.00 | 50.00 | |
| Duration of marriage (years) | 15.07 ± 8.55 | 0.16 | 33.00 | |
| Disease duration (years) | 7.37 ± 5.40 | 0.02 | 26 | |
| Age at diagnosis (years) | 27.92 ± 7.57 | 11.00 | 49.50 | |
| EDSS | 2.06 ± 1.85 | 0.00 | 7.50 | |
| Fatigue | 3.65 ± 1.57 | 1.00 | 7.00 | |
| Anxiety | 13.18(9.18) | 0 | 20 | |
| Depression | 13.46(9.57) | 0 | 28 | |
| Stress | 19.59(10.03) | 0 | 34 | |
| QOL | Physical health composite score | 62.66 ± 19.15 | 15.42 | 96.24 |
| Mental health composite score | 60.75 ± 19.99 | 9.07 | 97.34 | |
Education N (%) | Secondary school or below | 74 (24.7) | ||
| High school | 132 (44.0) | |||
| University | 94 (31.3) | |||
Occupation N (%) | Housewife | 258 (86.0) | ||
| Employed | 33 (11.0) | |||
| Retired | 9 (3.0) | |||
Disease pattern N (%) | Relapsing-Remitting MS (RRMS) | 243 (81.0) | ||
| Progressive MS | 39 (13.0) | |||
| Clinically Isolated Syndrome (CIS) | 18 (6.0) | |||
Taking medications N (%) | No | 30 (10.0) | ||
Yes 270 (90.0) | Disease Modifying Therapy (DMT) | 141 (47.0) | ||
| Anticholinergic drugs | 51 (17.0) | |||
| Psychiatric drugs | 8 (2.7) | |||
| Antidepressants drugs | 56(18.7) | |||
| Benzodiazepines drugs | 18(6.0) | |||
| Anticonvulsants drugs | 50(16.7) | |||
| Beta blockers drugs | 17 (5.7) | |||
| Antispasmodic drugs (baclofen,tizanidine, Methocarbamol) | 38(12.7) | |||
| Complementary drugs | 183 (61.0) | |||
The prevalence of sexual dysfunction and its mean score in married women with MS
| Domain | Cut-Off Point | N (%) | Mean (±SD) | Max/Min |
|---|---|---|---|---|
| Desire | 3.3 | 116 (38.7) | 3.41 (1.05) | 6.00/1.20 |
| Arousal | 3.4 | 116 (38.3) | 3.61 (1.18) | 6.00/1.20 |
| Lubrication | 3.7 | 104 (34.7) | 4.28 (1.28) | 6.00/1.20 |
| Orgasm | 3.4 | 112 (37.3) | 3.76 (1.27) | 6.00/1.20 |
| Satisfaction | 3.8 | 69 (23.0) | 4.57 (1.16) | 6.00/1.20 |
| Pain | 3.8 | 52 (17.3) | 4.99 (1.18) | 6.00/1.20 |
| Total | 28 | 211 (70.3) | 24.64 (5.11) | 34.40/7.20 |
The relationship between the six domains of the FSFI and demographic and clinical variables in the study subjects
| FSFI Domain | Desire | Arousal | Lubrication | Orgasm | Satisfaction | Pain | Total Sexual Dysfunction | |
|---|---|---|---|---|---|---|---|---|
| Age | r | −0.212** | −0.238** | −0.119* | − 0.156** | − 0.154** | 0.153** | − 0.166** |
| p | < 0.001 | < 0.001 | 0.040 | 0.007 | 0.008 | 0.008 | 0.004 | |
| Duration of marriage (years) | r | −0.171** | − 0.237** | − 0.150** | − 0.169** | −0.141* | 0.153** | −0.166** |
| p | 0.003 | < 0.001 | 0.009 | 0.003 | 0.015 | 0.008 | 0.004 | |
| Fatigue | r | −0.173** | −0.226** | −0.261** | − 0.234** | −0.252** | − 0.195** | −0.313** |
| p | 0.003 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | 0.001 | < 0.001 | |
| Age at diagnosis | r | −0.107 | − 0.137* | 0.021 | − 0.049 | −0.041 | 0.195** | −0.024 |
| p | 0.065 | 0.018 | 0.711 | 0.397 | 0.475 | 0.001 | 0.673 | |
| Anxiety | r | 0.070 | −0.094 | 0.009 | − 0.105 | −0.093 | 0.008 | −0.054 |
| p | 0.229 | 0.104 | 0.879 | 0.069 | 0.109 | 0.887 | 0.349 | |
| Depression | r | 0.007 | −0.200** | −0.066 | −0.147* | − 0.118* | −0.043 | − 0.135* |
| p | 0.900 | < 0.001 | 0.252 | 0.011 | 0.040 | 0.453 | 0.020 | |
| Stress | r | 0.114* | −0.076 | 0.028 | −0.075 | − 0.060 | −0.043 | − 0.029 |
| p | 0.048 | 0.189 | 0.627 | 0.195 | 0.301 | 0.454 | 0.613 | |
| Disease duration (years) | r | −0.069 | −0.041 | −0.147* | − 0.173** | −0.101 | − 0.044 | −0.106 |
| p | 0.235 | 0.483 | 0.011 | 0.003 | 0.082 | 0.450 | 0.068 | |
| EDSS | r | −0.071 | −0.148* | −0.127* | − 0.173** | −0.154** | − 0.024 | −0.164** |
| p | 0.219 | 0.010 | 0.028 | 0.003 | 0.008 | 0.676 | 0.004 | |
| Physical health composite score | r | 0.257** | 0.368** | 0.319** | 0.323** | 0.365** | 0.195** | 0.427** |
| p | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | 0.001 | < 0.001 | |
| Mental health composite score | r | 0.225** | 0.300** | 0.212** | 0.290** | 0.303** | 0.193** | 0.354** |
| p | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | 0.001 | < 0.001 | |
| MS Pattern Mean (SD) | ||||||||
| CIS | 18 | 3.46(0.76) | 3.58(1.14) | 5.01(0.86) | 3.51(1.40) | 4.97(1.18) | 5.20(0.87) | 25.75(4.18) |
| RRMS | 243 | 3.42(1.06) | 3.66(1.16) | 4.27(1.26) | 3.84(1.26) | 4.57(1.13) | 4.94(1.20) | 24.73(5.17) |
| Progressives | 39 | 3.35(1.09) | 3.28(1.26) | 4.02(1.47) | 3.37(1.13) | 4.35(1.29) | 5.16(1.12) | 23.56(5.02) |
| ANOVA | F | 0.093 | 1.760 | 3.819 | 2.750 | 1.755 | 0.871 | 1.337 |
| P | 0.911 | 0.174 | 0.023 | 0.066 | 0.175 | 0.420 | 0.264 | |
| Education Mean (SD) | ||||||||
| Secondary school or below | 74 | 3.29(1.21) | 3.25(1.28) | 3.98(1.50) | 3.46(1.36) | 4.37(1.27) | 5.23(1.18) | 23.58(5.72) |
| High school | 132 | 3.43(0.996) | 3.72(1.21) | 4.40(1.19) | 3.89(1.23) | 4.57(1.18) | 4.95(1.15) | 24.95(5.14) |
| University | 94 | 3.50(.990) | 3.74(0.99) | 4.37(1.20) | 3.82(1.21) | 4.74(1.02) | 4.86(1.22) | 25.04(4.46) |
| ANOVA | F | 0.811 | 4.685 | 2.844 | 2.866 | 2.029 | 2.097 | 2.113 |
| P | 0.445 | 0.010 | 0.060 | 0.058 | 0.133 | 0.125 | 0.123 | |
P-value resulted from Pearson’s test and ANOVA,
**. Correlation is significant at the 0.01 level (2-tailed),
*. Correlation is significant at the 0.05 level (2-tailed)
Multivariable Logistic regression analysis of women with multiple sclerosis and sexual dysfunction
| Characteristic | Unadjusted odds ratio (95% CI) | P | Adjusted odds ratio (95% CI) | P* |
|---|---|---|---|---|
| Age (years) | 1.032 (0.997 to 1.069) | 0.073 | 1.133 (0.933 to 1.306) | 0.085 |
| Marriage duration (years) | 1.020 (0.990 to 1.050) | 0.193 | 0.981 (0.918 to 1.047) | 0. 559 |
| Fatigue | 1.254 (1.064 to 1.478) | 0.007 | 1.228 (1.003 to 1.504) | 0.047 |
| EDSS* | 1.101 (0.957 to 1.267) | 0.177 | 0.987 (0.788 to 1.235) | 0.907 |
| BMI** | 1.071(1.004 to 1.143) | 0.037 | 1.071 (0.998 to 1.149) | 0.055 |
| Depression | 1.013 (0.986 to 1.040) | 0.355 | 1.023 (0.973 to 1.076) | 0.367 |
| Anxiety | 1.008 (0.981 to 1.036) | 0.572 | 1.012 (0.962 to 1.065) | 0. 638 |
| Stress | 0.999 (0.975 to 1.024) | 0.938 | 0.971 (0.925 to 1.019) | 0. 230 |
| Disease duration(years) | 1.015 (0.969 to 1.063) | 0.540 | 0.916 (0.803 to 1.046) | 0.195 |
| Age at diagnosis(years) | 1.011(9.979 to 1.045) | 0.532 | 0.920(0.813 to 1.041) | 0.184 |
| Disease Modifying Therapy(DMT) | 1.149(0.700–1.887) | 0.583 | 1.002(0.574 to 1.749) | 0.994 |
| Antidepressants drugs | 0.520(0.255–1.060 | 0.072 | 0.641(0.294 to 1.398) | 0.264 |
| Anticonvultion drugs | 0.541(0.258 to 1.137) | 0. 105 | 0.708(0.311 to 1.609) | 0.410 |
| Antispasmodic drugs | 0.827(0.384 to 1.785) | 0.629 | 1.099(0.440 to 2.745) | 0.840 |
| Course disease | ||||
| Relapsing remitting | 0.878 (9.302 to 2.553) | 0.812 | 0.806 (0. 328 to 1.979) | 0. 638 |
| Progressive | 1.115 (.317 to 3.921) | 0.865 | 0.807 (0.420 to 1.551) | 0.520 |
| CIS*** | Ref | |||
| education | ||||
| Secondary school or below | 1.145(0.582–2.255) | 0.694 | 0.806(0.328 to 1.979) | 0.638 |
| High school | 0.942(0.530–1.674) | 0.838 | 0.807(0.420 to 1.551) | 0.520 |
| University | Ref | |||
EDSS*, Expanded Disability Status Scale. BMI**, Body Mass Index. CIS***, Clinical Isolated Syndrome. OR adjusted based on individual variables (age, duration of marriage, BMI, education) and clinical variables (age of onset of disease, disease duration, EDSS, course disease, Fatigue, anxiety, depression, stress, Antidepressants drug, Disease Modifying Therapy (DMT), Antispasmodic and Anticonvultion drugs)
A comparison of the mean scores of quality of life (QOL) in women with MS with and without Sexual dysfunction (SD)
| QOL Domain | Without SD | with SD | t | P |
|---|---|---|---|---|
| Mean (SD) | Mean (SD) | |||
| Physical function | 71.85 (28.69) | 60.68 (29.78( | 2.998 | 0.003 |
| Role limitation due to physical problems | 54.49 (44.36) | 43.36 (43.75) | 2.004 | 0.046 |
| Role limitation due to emotional problems | 51.31 (47.95) | 40.91 (45.37) | 1.742 | 0.083 |
| Pain | 83.85 (21.30) | 69.49 (24.72) | 5.079 | < 0.001 |
| Emotional well-being | 65.52 (18.61) | 57.59 (21.13) | 3.072 | 0.002 |
| Energy | 55.55 (20.32) | 49.04 (21.15) | 2.460 | 0.014 |
| Health perceptions | 60.84 (20.17) | 55.59 (20.47) | 2.038 | 0.042 |
| Social function | 82.49 (16.95) | 72.59 (22.01) | 4.212 | < 0.001 |
| Cognitive function | 80.00(21.63) | 70.40 (25.48) | 3.323 | 0.001 |
| Health distress | 75.00 (23.60) | 68.10 (27.47) | 2.067 | 0.040 |
| Sexual function | 93.70 (13.70) | 62.48 (26.09) | 13.346 | < 0.001 |
| Change in health | 51.40 (29.03) | 47.81 (26.15) | 1.046 | 0.297 |
| Satisfaction with sexual function | 85.17 (21.13) | 55.76 (30.44) | 9.466 | < 0.001 |
| Overall QOL | 72.05 (15.69) | 64.40 (18.40) | 3.430 | 0.001 |
| Physical health composite score | 69.97 (17.02) | 59.63 (19.20) | 4.336 | < 0.001 |
| Mental health composite score | 66.78 (19.13) | 58.21 (19.85) | 3.455 | 0.001 |
FSFI Female Sexual Function Index